187 related articles for article (PubMed ID: 37188125)
21. Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia.
Soof CM; Spektor TM; Parikh SA; Slager SL; Rabe KG; Call TG; Kenderian SS; Ding W; Muchtar E; Ghermezi M; Kay NE; Berenson JR
Exp Hematol; 2022 Jul; 111():32-40. PubMed ID: 35525334
[TBL] [Abstract][Full Text] [Related]
22. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.
Chen H; Li M; Xu N; Ng N; Sanchez E; Soof CM; Patil S; Udd K; Bujarski S; Cao J; Hekmati T; Ghermezi M; Zhou M; Wang EY; Tanenbaum EJ; Zahab B; Schlossberg R; Yashar MA; Wang CS; Tang GY; Spektor TM; Berenson JR
Leuk Res; 2019 Jun; 81():62-66. PubMed ID: 31035033
[TBL] [Abstract][Full Text] [Related]
23. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.
Ghermezi M; Li M; Vardanyan S; Harutyunyan NM; Gottlieb J; Berenson A; Spektor TM; Andreu-Vieyra C; Petraki S; Sanchez E; Udd K; Wang CS; Swift RA; Chen H; Berenson JR
Haematologica; 2017 Apr; 102(4):785-795. PubMed ID: 28034989
[TBL] [Abstract][Full Text] [Related]
24. Estimating a normal reference range for serum B-cell maturation antigen levels for multiple myeloma patients.
Jew S; Bujarski S; Soof C; Chen H; Safaie T; Li M; Sanchez E; Wang C; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Spektor TM; Berenson JR
Br J Haematol; 2021 Mar; 192(6):1064-1067. PubMed ID: 32321191
[TBL] [Abstract][Full Text] [Related]
25. Soluble B-cell maturation antigen in multiple myeloma.
Costa BA; Ortiz RJ; Lesokhin AM; Richter J
Am J Hematol; 2024 Apr; 99(4):727-738. PubMed ID: 38270277
[TBL] [Abstract][Full Text] [Related]
26. Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients.
Salazar-Camarena DC; Palafox-Sánchez CA; Cruz A; Marín-Rosales M; Muñoz-Valle JF
Sci Rep; 2020 Apr; 10(1):6236. PubMed ID: 32277232
[TBL] [Abstract][Full Text] [Related]
27. Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma.
Meinl E; Krumbholz M
Curr Opin Immunol; 2021 Aug; 71():117-123. PubMed ID: 34330018
[TBL] [Abstract][Full Text] [Related]
28. The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma.
Sanchez E; Smith EJ; Yashar MA; Patil S; Li M; Porter AL; Tanenbaum EJ; Schlossberg RE; Soof CM; Hekmati T; Tang G; Wang CS; Chen H; Berenson JR
Target Oncol; 2018 Feb; 13(1):39-47. PubMed ID: 29230672
[TBL] [Abstract][Full Text] [Related]
29. Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients.
Jew S; Bujarski S; Regidor B; Emamy-Sadr M; Swift R; Eades B; Kim S; Eshaghian S; Berenson JR
Target Oncol; 2023 Sep; 18(5):735-747. PubMed ID: 37682503
[TBL] [Abstract][Full Text] [Related]
30. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
Front Immunol; 2021; 12():755866. PubMed ID: 34777368
[TBL] [Abstract][Full Text] [Related]
31. Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports.
Xu J; Ming X; Wang C; Xu B; Xiao Y
Medicine (Baltimore); 2021 May; 100(18):e25784. PubMed ID: 33950974
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q
Front Immunol; 2021; 12():720571. PubMed ID: 34421924
[TBL] [Abstract][Full Text] [Related]
33. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
34. The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma.
Xu Y; Mao X; Que Y; Xu M; Li C; Almeida VDF; Wang D; Li C
BMC Cancer; 2023 Feb; 23(1):123. PubMed ID: 36750969
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
Kyle RA; Durie BG; Rajkumar SV; Landgren O; Blade J; Merlini G; Kröger N; Einsele H; Vesole DH; Dimopoulos M; San Miguel J; Avet-Loiseau H; Hajek R; Chen WM; Anderson KC; Ludwig H; Sonneveld P; Pavlovsky S; Palumbo A; Richardson PG; Barlogie B; Greipp P; Vescio R; Turesson I; Westin J; Boccadoro M;
Leukemia; 2010 Jun; 24(6):1121-7. PubMed ID: 20410922
[TBL] [Abstract][Full Text] [Related]
36. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K
Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662
[TBL] [Abstract][Full Text] [Related]
37. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
38. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
[TBL] [Abstract][Full Text] [Related]
39. Plasma cell neoplasms and related entities-evolution in diagnosis and classification.
Fend F; Dogan A; Cook JR
Virchows Arch; 2023 Jan; 482(1):163-177. PubMed ID: 36414803
[TBL] [Abstract][Full Text] [Related]
40. Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis.
Mahler MR; Søndergaard HB; Buhelt S; von Essen MR; Romme Christensen J; Enevold C; Sellebjerg F
Mult Scler Relat Disord; 2020 Oct; 45():102391. PubMed ID: 32679525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]